Eylea HD Approval And STEM Focus Shape Regeneron’s Growth Outlook

Simply Wall St.01-28

Regeneron Pharmaceuticals received regulatory approval for Eylea HD with expanded indications and has begun launching the product. The company is also highlighting its long running Regeneron Science ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606759851?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919","is_english":true,"pubTime":"2026-01-28 03:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606759851","market":"hk","top_or_hot":-1,"title":"Eylea HD Approval And STEM Focus Shape Regeneron’s Growth Outlook","media":"Simply Wall St.","content":"<div>\n<p>Regeneron Pharmaceuticals received regulatory approval for Eylea HD with expanded indications and has begun launching the product. The company is also highlighting its long running Regeneron Science ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/eylea-hd-approval-and-stem-focus-shape-regenerons-growth-out\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eylea HD Approval And STEM Focus Shape Regeneron’s Growth Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEylea HD Approval And STEM Focus Shape Regeneron’s Growth Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-28 03:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/eylea-hd-approval-and-stem-focus-shape-regenerons-growth-out><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regeneron Pharmaceuticals received regulatory approval for Eylea HD with expanded indications and has begun launching the product. The company is also highlighting its long running Regeneron Science ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/eylea-hd-approval-and-stem-focus-shape-regenerons-growth-out\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0354030438.USD","symbol_name":"富国美国大盘成长基金Cl A Acc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/eylea-hd-approval-and-stem-focus-shape-regenerons-growth-out","article_id":"2606759851","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/eylea-hd-approval-and-stem-focus-shape-regenerons-growth-out","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2606759851","pubTimestamp":1769541634,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Regeneron Pharmaceuticals received regulatory approval for Eylea HD with expanded indications and has begun launching the product.\nThe company is also highlighting its long running Regeneron Science Talent Search as part of a broader push into STEM education support.\nThese developments are material for investors because they touch both the commercial outlook for Eylea HD and Regeneron's long term brand and stakeholder relationships.\n\nFor investors watching NasdaqGS:REGN, the approval and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","BK4550":"红杉资本持仓","BK4588":"碎股","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","REGN":"再生元制药公司","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","HD":"家得宝","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4581":"高盛持仓","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4139":"生物科技","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","STEM":"Stem Inc.","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","BK4083":"家庭装潢零售","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0058720904.USD":"联博国际健康护理基金A","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC"},"translate_title":"Eylea HD批准和STEM重点塑造再生元的增长前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":0.9,"HD":1.5,"STEM":1.5},"content_text":"Regeneron Pharmaceuticals received regulatory approval for Eylea HD with expanded indications and has begun launching the product. The company is also highlighting its long running Regeneron Science Talent Search as part of a broader push into STEM education support. These developments are material for investors because they touch both the commercial outlook for Eylea HD and Regeneron's long term brand and stakeholder relationships.  For investors watching NasdaqGS:REGN, the approval and launch of Eylea HD arrive as the shares trade around $762.65, with a 12.0% return over the past year and a 50.9% return over five years. Those figures help frame how the market has been valuing Regeneron Pharmaceuticals as it competes in crowded ophthalmology and broader biologics markets. Looking ahead, Eylea HD with expanded indications could influence how Regeneron balances growth opportunities against competitive pressures in retinal therapies. At the same time, the ongoing Regeneron Science Talent Search and STEM education focus may support the company’s reputation with patients, researchers and policymakers, which can matter over long investment horizons. Stay updated on the most important news stories for Regeneron Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Regeneron Pharmaceuticals. NasdaqGS:REGN Earnings & Revenue Growth as at Jan 2026 How Regeneron Pharmaceuticals stacks up against its biggest competitors AdvertisementQuick Assessment  ✅ Price vs Analyst Target: The current price of $762.65 is about 8% below the US$831.38 analyst consensus target. ✅ Simply Wall St Valuation: Simply Wall St currently views Regeneron as trading around 55.9% below its estimated fair value. ❌ Recent Momentum: The share price has seen a 2.8% decline over the last 30 days.  Check out Simply Wall St's\nin-depth valuation analysis for Regeneron Pharmaceuticals. Key Considerations  📊 Eylea HD approvals with broader indications may be important for sustaining Regeneron’s retinal franchise as competition in eye drugs remains intense. 📊 Watch prescription uptake trends for Eylea HD, any pricing commentary, and how management discusses STEM programs like the Regeneron Science Talent Search in relation to long-term priorities. ⚠️ Key risks to track include possible payer pressure, rival retinal treatments, and any regulatory shifts that could affect the Eylea HD opportunity.  Dig Deeper For the full picture, including more risks and potential rewards, check out the\ncomplete Regeneron Pharmaceuticals analysis.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606759851","isCrawlerRequest":true}